| Name | Title | Contact Details |
|---|---|---|
Nicholas Khadder |
General Counsel and Corporate Secretary | Profile |
Meditrina, a startup company located in Cupertino, CA, was founded in 2016, and developed the Aveta™ System, a single-use Hysteroscope and Resecting Device, with an all-inclusive HD Visualization and Fluid Management system. A new office Hysteroscopy system which can also be used in the clinic or hospital operating room (OR), for diagnostic or therapeutic Hysteroscopy procedures. Procedures include: Diagnostic Hysteroscopy, biopsy, and soft tissue removal such as, fibroids, polyps, and/or retained products of conception (RPOC).
VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the oncology suite and give an oncology team the ability to measure the dosage of radiation delivered to a patient on a per treatment basis. The data collected from our dosimeter technologies is invaluable when recording the total amount of radiation that a patient is exposed to during the entire treatment regimen, and the data can be used on a generic basis to develop future treatment regimens and evidence-based healthcare. VeriTeQ is developing an informatics and data analytics platform that will improve the type of medical device and treatment regimen data that can be used in many applications to improve patient healthcare and outcomes. Such examples include using VeriTeQ's UDI data in supply chain management for medical device manufacturers and healthcare institutions, quality and reimbursement controls for hospitals, and treatment regimen data for patients receiving chemotherapy and radiation therapy. VeriTeQ owns a rich portfolio of intellectual property protecting all of its current and future technologies.
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn`t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world`s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.
Lakeland Automatic Doors, L C is a Altoona, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Anspach Effort, Inc. is a successful, continuously evolving business whose focus concentrates on high-speed instrumentation for Neurosurgery, Neurotology, Otology, and Orthopedics. The company is committed to providing product quality, technology,